WYWei Yang

Wei Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wei Yang has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Sono‐Tribocatalytic Whole Tumor Cell Vaccine Enables Ultrasound‐Controlled Immune Boosting for Enhanced Anti‐Tumor Immunity

    by Hongze Ren, Qingying Wu, Wei Yang, Zhengqi Tang, Lili Xia, Chenyao Wu, Xinyue Dai, Hui Huang, Yu Chen

    Whole tumor cell vaccines are uniquely positioned for personalized immunotherapy by presenting the full repertoire of tumor‐associated antigens to counter tumor heterogeneity, yet their translation is persistently hindered by poor immunogenicity and the requirement for multiple administrations. Herein, we introduce a sono‐tribocatalytic vaccine platform by integrating MnVO 3 nanosheets into tumor cells, enabling ultrasound‐controlled immune boosting following a single vaccination. Upon a single subcutaneous injection, non‑invasive ultrasound irradiation triggers intense interfacial friction between the nanosheets and surrounding tissue fluids, driving efficient generation of reactive oxygen species via triboelectric charge transfer and concurrent release of metal ions that orchestrate metal‑immune crosstalk. This unique sono‑tribocatalytic process establishes a spatiotemporally remote control of localized inflammation to function as an on‐demand “sono‐booster.” Mechanistically, this sono‐booster reprograms the local immune microenvironment by amplifying oxidative stress and inflammatory signaling, thereby promoting dendritic cell maturation and antigen cross‑presentation to elicit antigen‑specific T cell responses. Remarkably, a single dose of this sono‑tribocatalytic vaccine achieves potent anti‐tumor efficacy across multiple preclinical models. By enabling on‑demand, non‑invasive immune boosting from a single injection through a sono‑tribocatalytic mechanism, this vaccine platform establishes an externally controllable strategy for enhancing vaccine‐induced immunity and offers a versatile framework for next‐generation cancer immunotherapy.

  • Sono‐Tribocatalytic Whole Tumor Cell Vaccine Enables Ultrasound‐Controlled Immune Boosting for Enhanced Anti‐Tumor Immunity

    by Hongze Ren, Qingying Wu, Wei Yang, Zhengqi Tang, Lili Xia, Chenyao Wu, Xinyue Dai, Hui Huang, Yu Chen

    Whole tumor cell vaccines are uniquely positioned for personalized immunotherapy by presenting the full repertoire of tumor‐associated antigens to counter tumor heterogeneity, yet their translation is persistently hindered by poor immunogenicity and the requirement for multiple administrations. Herein, we introduce a sono‐tribocatalytic vaccine platform by integrating MnVO 3 nanosheets into tumor cells, enabling ultrasound‐controlled immune boosting following a single vaccination. Upon a single subcutaneous injection, non‑invasive ultrasound irradiation triggers intense interfacial friction between the nanosheets and surrounding tissue fluids, driving efficient generation of reactive oxygen species via triboelectric charge transfer and concurrent release of metal ions that orchestrate metal‑immune crosstalk. This unique sono‑tribocatalytic process establishes a spatiotemporally remote control of localized inflammation to function as an on‐demand “sono‐booster.” Mechanistically, this sono‐booster reprograms the local immune microenvironment by amplifying oxidative stress and inflammatory signaling, thereby promoting dendritic cell maturation and antigen cross‑presentation to elicit antigen‑specific T cell responses. Remarkably, a single dose of this sono‑tribocatalytic vaccine achieves potent anti‐tumor efficacy across multiple preclinical models. By enabling on‑demand, non‑invasive immune boosting from a single injection through a sono‑tribocatalytic mechanism, this vaccine platform establishes an externally controllable strategy for enhancing vaccine‐induced immunity and offers a versatile framework for next‐generation cancer immunotherapy.

  • Open Access

    One-dimensional nanosonosensitizer boosted multiple branches of immune responses against MHC-deficient immune-evasive urologic tumor

    by Wei Yang, Sichen Di, Zihuan Yang, Jianwei Cao, Qingqiao Fu, Hongze Ren, Hui Cheng, Yujie Xie, Wencong Jia, Xinyue Dai, et al.

    Cancer immunotherapies rely on CD8 + cytolytic T lymphocytes (CTLs) in recognition and eradication of tumor cells via antigens presented on major histocompatibility complex class I (MHC-I) molecules. However, we observe MHC-I deficiency in human and murine urologic tumors, posing daunting challenges for successful immunotherapy. We herein report an unprecedented nanosonosensitizer of one-dimensional bamboo-like multisegmented manganese dioxide@manganese–bismuth vanadate (BMMBV) to boost multiple branches of immune responses targeting MHC-I–deficient tumors. BMMBV markedly augments sonodynamic activity contributed by manganese heteroatoms in the lattice of bismuth vanadate with narrowing bandgaps. Under sonoirradiation, BMMBV enhances tumor antigen spreading and emission of adjuvant signals, which potentiate dendritic cell maturation, thereby eliciting high aptitude of CTLs. This therapy substantially up-regulates MHC expression on tumor cells, which are reversely sensitive to CTLs. Alongside, extensive innate immune cells complement the cytolytic activity of CTLs for eliminating mouse urologic tumors. This study offers a reinforced strategy against antigen-loss immune-evasive tumor.


  • Open Access

    ENO2 affects the EMT process of renal cell carcinoma and participates in the regulation of the immune microenvironment

    by Wei-Jie Chen, Wei Yang, Min Gong, Yi He, Da Xu, Jia-Xin Chen, Wen-Jin Chen, Wen-Yan Li, Yu-Qi Wang, Ke-Qin Dong, et al.

    Clear cell renal cell carcinoma (ccRCC) is a frequent malignant tumor of the kidney which has a dismal prognosis. At present, targeted therapies and immunotherapy have achieved significant results; however, the overall survival rate of patients with ccRCC remains unacceptably poor. It is therefore necessary to find novel therapeutic and diagnostic targets for ccRCC. It has been reported that enolase 2 (ENO2) is an oncogene, although its function in the immune microenvironment and in the growth of ccRCC has yet to be fully elucidated. The present study analyzed the data of patients with ccRCC both from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases, and from clinical samples obtained from Third Affiliated Hospital of the Second Military Medical University to investigate the role of ENO2 in the progression of ccRCC and the correlation between ENO2 and certain clinical features. It was found that the expression of ENO2 was elevated both in patients with ccRCC retrieved from the GEO and TCGA databases and in clinical ccRCC samples obtained from Third Affiliated Hospital of the Second Military Medical University. In addition, the prognosis of patients was poorer when ENO2 was highly expressed. Gene Ontology (GO) analysis and Gene Set Enrichment Analysis (GSEA) confirmed that ENO2 participated in the regulation of various pathways in ccRCC. In vitro experiments including Cell Counting Kit‑8 cell proliferation assay, Transwell and Matrigel assays confirmed that ENO2 could promote the proliferation and migration of ccRCC cells. Furthermore, a number of immunosuppressive indicators were identified that positively correlated with ENO2 expression. In conclusion, the present study revealed that ENO2 expression promotes the proliferation, invasion and migration of ccRCC cells, and may serve as a novel predictor to evaluate prognosis and the efficacy of immune checkpoint blockade treatment for patients with ccRCC.


  • Open Access

    Nanoformulations targeting immune cells for cancer therapy: mRNA therapeutics

    by Wei Yang, Jianwei Cao, Hui Cheng, Liang Chen, Meihua Yu, Yu Chen, Xingang Cui

    The approved worldwide use of two messenger RNA (mRNA) vaccines (BNT162b2 and mRNA-1273) in late 2020 has proven the remarkable success of mRNA therapeutics together with lipid nanoformulation technology in protecting people against coronaviruses during COVID-19 pandemic. This unprecedented and exciting dual strategy with nanoformulations and mRNA therapeutics in play is believed to be a promising paradigm in targeted cancer immunotherapy in future. Recent advances in nanoformulation technologies play a prominent role in adapting mRNA platform in cancer treatment. In this review, we introduce the biologic principles and advancements of mRNA technology, and chemistry fundamentals of intriguing mRNA delivery nanoformulations. We discuss the latest promising nano-mRNA therapeutics for enhanced cancer immunotherapy by modulation of targeted specific subtypes of immune cells, such as dendritic cells (DCs) at peripheral lymphoid organs for initiating mRNA cancer vaccine-mediated antigen specific immunotherapy, and DCs, natural killer (NK) cells, cytotoxic T cells, or multiple immunosuppressive immune cells at tumor microenvironment (TME) for reversing immune evasion. We highlight the clinical progress of advanced nano-mRNA therapeutics in targeted cancer therapy and provide our perspectives on future directions of this transformative integrated technology toward clinical implementation.


  • Open Access

    Phase Ⅱ Study of Fully Human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

    by Wenming Chen, Chengcheng Fu, Baijun Fang, Aibin Liang, Zhongjun Xia, Yanjuan He, Jin Lu, Hui Liu, Ming Hou, Zhen Cai, et al.

    Background: Zevorcabtagene autoleucel (Zevor-cel, CT053), a fully human autologous anti- B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell